Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Lake Isabella › NPI 1427049964
Nursing facility

Kern Valley Healthcare District

Kern Valley Healthcare District was paid $13.18M by Medicaid between Jan 2018 and Dec 2024, across 174 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.

33Billing provider infoKERN VALLEY HEALTHCARE DISTRICT
LAKE ISABELLA, CA 93240
33aNPI1427049964assigned 11/03/2005
33bProvider typeSkilled Nursing Facility
28Total paid$13.18M
24GClaims298,227
24DCodes billed174
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Skilled Nursing Facility providers in California

Rank by total paid#10 of 547
Median peer was paid$73K
This provider vs. median180×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201844,423$2.71M
201945,962$2.61M
202039,176$1.39M
202141,513$1.57M
202243,433$1.61M
202346,130$1.87M
2024incomplete37,590$1.42M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 20% 13,429 12,411 $2.57M
T1015 A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive 19% 11,122 9,070 $2.53M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 17% 9,839 8,856 $2.25M
0450 Emergency room services 6.5% 8,060 7,119 $862K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 6.0% 25,809 22,146 $796K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 4.6% 11,922 2,820 $609K
0270 2.9% 5,201 4,480 $385K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 2.8% 4,722 4,598 $373K
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 2.5% 9,046 8,073 $323K
Q3014 Telehealth originating site facility fee 1.4% 8,286 6,643 $186K
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis 1.2% 3,917 2,576 $163K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.1% 1,499 1,452 $146K
162 more codes
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 5,847 $127K
70450 Computed tomography, head or brain; without contrast material <1% 2,216 $114K
G0467 Community health center visit, returning patient <1% 2,100 $108K
J3490 Unclassified drugs <1% 11,070 $95K
80053 Comprehensive metabolic panel <1% 12,220 $89K
96361 Intravenous infusion, hydration; each additional hour <1% 3,662 $69K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 12,703 $59K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 2,457 $57K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,644 $54K
71046 Radiologic examination, chest; 2 views <1% 2,739 $53K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 1,838 $53K
96375 Therapeutic injection; each additional sequential IV push <1% 3,283 $52K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 5,364 $50K
71275 Computed tomographic angiography, chest, with contrast material <1% 468 $48K
84443 Thyroid stimulating hormone (TSH) <1% 3,147 $48K
99223 Prolong inpt eval add15 m <1% 553 $44K
83880 <1% 3,538 $44K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 3,146 $43K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 674 $36K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 1,413 $32K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 811 $28K
83605 <1% 5,734 $28K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 683 $28K
80061 Lipid panel <1% 1,678 $28K
84484 <1% 5,624 $28K
71045 Radiologic examination, chest; single view <1% 4,677 $25K
97161 <1% 662 $24K
73630 <1% 848 $23K
72125 Computed tomography, cervical spine; without contrast material <1% 283 $22K
90707 <1% 309 $21K
92552 <1% 1,101 $21K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,865 $18K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) <1% 337 $18K
97139 <1% 1,350 $18K
99392 Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) <1% 377 $17K
J7030 Infusion, normal saline solution , 1000 cc <1% 4,524 $17K
83036 Hemoglobin; glycosylated (A1C) <1% 1,178 $16K
99239 Hospital discharge day management, more than 30 minutes <1% 307 $14K
82550 <1% 4,440 $14K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 536 $13K
83735 <1% 3,353 $12K
83690 <1% 3,576 $12K
85610 <1% 5,336 $11K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,272 $11K
84439 <1% 996 $11K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 440 $10K
71250 <1% 77 $9K
85730 <1% 3,105 $9K
87040 <1% 1,198 $8K
90674 <1% 379 $8K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 272 $8K
99070 <1% 10,485 $7K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) <1% 118 $7K
82010 <1% 1,756 $7K
97163 <1% 205 $7K
99233 Hospital visit by a doctor, follow-up day (complex) <1% 207 $7K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,977 $7K
72110 <1% 172 $7K
81001 <1% 2,825 $7K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,891 $6K
81003 <1% 3,644 $6K
90715 <1% 332 $6K
73030 <1% 414 $6K
99173 <1% 1,149 $5K
73562 <1% 309 $5K
81025 <1% 2,191 $5K
90658 <1% 201 $5K
82948 <1% 1,050 $4K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 154 $4K
82553 <1% 898 $4K
85379 <1% 824 $4K
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,090 $4K
73130 <1% 199 $3K
Z7502 <1% 118 $3K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 139 $3K
73610 <1% 214 $3K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 780 $3K
80048 Basic metabolic panel (calcium, ionized) <1% 496 $3K
90649 <1% 26 $2K
82150 <1% 811 $2K
80305 <1% 362 $2K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 899 $2K
85378 <1% 671 $2K
87070 <1% 655 $2K
84145 <1% 433 $2K
0250 <1% 82 $2K
87088 <1% 527 $2K
99442 <1% 38 $2K
90700 <1% 84 $1K
87450 <1% 573 $1K
85651 <1% 894 $1K
86769 <1% 35 $1K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 46 $1K
96367 <1% 79 $1K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 31 $1K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 915 $1K
0320 <1% 14 $1K
90716 <1% 81 $1K
99201 <1% 33 $922.23
99203 Doctor's office visit, new patient (routine) <1% 12 $898.77
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 23 $885.22
84100 <1% 408 $873.91
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 422 $873.01
90670 <1% 75 $823.50
87186 <1% 300 $780.57
80074 <1% 13 $776.43
90713 <1% 38 $764.51
82043 <1% 104 $733.24
87077 <1% 379 $684.94
J7050 Infusion, normal saline solution, 250 cc <1% 233 $597.31
99391 Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) <1% 13 $548.08
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 37 $542.96
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 12 $485.05
72100 <1% 24 $474.15
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring <1% 15 $450.00
72050 <1% 25 $434.10
90734 <1% 12 $418.16
96376 <1% 15 $394.30
H0033 Oral medication administration, direct observation <1% 500 $391.62
0012A <1% 13 $369.07
J1170 Injection, hydromorphone, up to 4 mg <1% 79 $365.61
90633 <1% 28 $306.00
96127 <1% 49 $294.49
J2060 Injection, lorazepam, 2 mg <1% 190 $281.52
73502 <1% 12 $280.51
94760 <1% 69 $280.42
3080F <1% 263 $278.47
3077F <1% 414 $278.47
J2543 Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) <1% 12 $240.67
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 93 $213.12
A4216 Sterile water, saline and/or dextrose, diluent/flush, 10 ml <1% 86 $181.08
90744 <1% 13 $171.54
82140 <1% 40 $154.27
3079F <1% 211 $119.79
90686 <1% 32 $117.45
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 109 $92.07
84481 <1% 12 $87.74
J7120 Ringers lactate infusion, up to 1000 cc <1% 26 $87.08
36415 Collection of venous blood by venipuncture <1% 69 $75.10
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 15 $69.95
84703 <1% 27 $46.94
86580 <1% 37 $46.07
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 42 $45.80
87086 Culture, bacterial; quantitative colony count, urine <1% 15 $36.67
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 292 $30.40
J3010 Injection, fentanyl citrate, 0.1 mg <1% 12 $30.22
3044F <1% 13 $22.98
A4663 Blood pressure cuff only <1% 24 $22.15
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 13 $5.40
80349 <1% 81 $1.85
A6402 Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing <1% 82 $1.02
91301 <1% 92 $0.75
G8510 Screening for depression is documented as negative, a follow-up plan is not required <1% 30 $0.30
S0119 Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) <1% 12 $0.24
G8431 Screening for depression is documented as being positive and a follow-up plan is documented <1% 19 $0.19
80329 0% 34 $0.00
0250R 0% 70 $0.00
3075F 0% 63 $0.00
3074F 0% 170 $0.00
J1741 Injection, ibuprofen, 100 mg 0% 15 $0.00
3078F 0% 169 $0.00
0270R 0% 31 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialOLSON, JEANNE (BUSINESS OFFICE MANAGER)